[email protected] Study is a joint initiative of CIBERDEM, Sociedad Española de Diabetes (SED) and the now dissolved Federación Española de Diabetes (FED) having the objective of providing comprehensive knowledge concerning the epidemiology of type 2 diabetes mellitus in Spain.
CIBERDEM, the main funding entity of the study, supports and promotes [email protected] Study as a key study to know the incidence and prevalence of diabetes in the Spanish population. The results will allow public institutions of the National Health System to formulate more efficient and effective policies for the prevention, treatment and research of diabetes.
Objectives
- To determine the total prevalence (known and unknown) of type 2 diabetes mellitus in a representative sample of the Spanish population.
- To determine the relationship between the prevalence of type 2 diabetes mellitus and the eating habits and physical activity of the individuals from the sample, as well as relevant information relating to its demographic and genetic composition.
- To determine the prevalence of fasting glucose alteration and glucose tolerance alteration, insulin resistance, hypertension, dyslipidemia, obesity and metabolic syndrome in a representative sample of the Spanish population.
- To provide a scientific tool for advising the institutions of the National Health System.
- To determine the relationship between the prevalence of these illnesses and the eating habits and physical activity of individuals from the sample.
- To provide a collection of human serum and DNA samples for conducting studies on the analysis of gene-environment interaction in the pathogenesis of diabetes.
Calendar
For CIBERDEM, the second part of the [email protected] project is part of its strategic plan since conducting a prospective study with the same patients participating in the first phase will provide unprecedented, essential information.
Members
- Management Federico Soriguer (Hospital Carlos Haya-IMABIS, Malaga, and CIBERDEM)
- Coordination Gemma Pascual (CIBERDEM Technical Office) and Gemma Rojo (Hospital Carlos Haya-IMABIS, Malaga, and CIBERDEM)
- Northern Area Field Coordination and CIBERDEM Management: Luis Castaño (Hospital de Cruces, Bilbao, and CIBERDEM). Field work: Alicia Cobo, Ana María Megido
- North-Eastern Area Field Coordination: Albert Goday (Hospital del Mar, Barcelona). CIBERDEM Management: Ramon Gomis (Hospital Clínic de Barcelona, IDIBAPS, and CIBERDEM). Field work: Alba Arocas, Laura Esquius, Rosario Suarep, María Dolores Zomeño
- Levante Area Field Coordination: Miguel Catalá (Hospital Clínico de Valencia and CIBERDEM). CIBERDEM Management: Rafael Carmena (Hospital Clínico de Valencia and CIBERDEM). Field work: Clara Bixquert, Nieves Brito
- Central Area Field Coordination: Alfonso Calle (Hospital San Carlos, Madrid). CIBERDEM Management: Manuel Serrano Ríos (Hospital San Carlos, Madrid and CIBERDEM). Field work: Isabel Alonso, Enrique Mañas
- Southern Area Field Coordination: Gemma Rojo (Hospital Carlos Haya-IMABIS, Malaga, and CIBERDEM). CIBERDEM Management: Federico Soriguer (Hospital Carlos Haya-IMABIS, Malaga, and CIBERDEM). Field work: Rocío Badía, Isabel Guillén
- Other members: Alfonso López Alba (Hospital Universitario de Canarias, Tenerife), Elena Bordiu (Hospital San Carlos de Madrid), Roser Casamitjana (Hospital Clínic de Barcelona, IDIBAPS, y CIBERDEM), Conxa Castell (Consejo Asesor sobre la Diabetes Dirección General de Salud Pública, Generalitat de Catalunya, Barcelona), Elias Delgado (Hospital General de Asturias), Edelmiro Menéndez (Hospital Universitario Central de Astúrias), Josep Franch (Centre d’Atenció Primària Raval Sud, Barcelona), José A Vázquez (Hospital de Cruces, Bilbao), Sonia Gaztambide (Hospital de Cruces, Bilbao, y CIBERDEM), Juan Girbés (Hospital Arnau de Vilanova de Valencia), Maria Teresa Martínez-Larrad (Hospital San Carlos de Madrid, y CIBERDEM), Emilio Ortega (Hospital Clínic de Barcelona, IDIBAPS, y CIBERDEM), Inmaculada Mora (Hospital Universitario de Canarias, Tenerife), Sergio Valdés (Hospital Carlos Haya-IMABIS, Málaga, y CIBERDEM), Joan J Vendrell (Hospital Joan XXIII de Tarragona y CIBERDEM).
As a continuation of the [email protected] study, CIBERDEM has launched the [email protected] study II to determine the incidence of type 2 diabetes in Spain. It relates to a prospective cohort study where the same cohort will be studied after 6 years to study the prevalence [email protected]. The incidence of type 2 diabetes, obesity and metabolic syndrome and the main risk factors, diet and physical inactivity will be determined. The predictive value of the currently available risk indices will also be evaluated. Blood samples are stored in the CIBERDEM-IDIBAPS Biorepository for Diabetes and Metabolic Diseases and will be available to the researchers requesting them. The results of the [email protected] study II, together with the results of [email protected] study I will constitute an essential tool for designing preventive strategies in diabetes in Spain as well as for evaluating their effectiveness.
